Recent Progress of Biomarker Detection Sensors

Liu, Ruitao; Ye, Xiongying; Cui, Tianhong

doi:10.34133/2020/7949037

Cited by 49 publications

(41 citation statements)

References 191 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even nucleic acid biomarkers can now be detected within minutes, with recent publications reporting completion of 30 qPCR cycles within 54 s ( 133 ), certainly fast enough for stroke diagnostics if the promise of portable devices that might be used at the bedside ( 134 ) are realized. Moreover, nanotechnology offers the promise of highly multiplexed biosensors capable of rapid simultaneous analysis of large panels of biomarkers ( 135 ), an important consideration if multiple analytes must be assessed to provide stroke diagnosis and prognosis.…”

Section: Discussionmentioning

confidence: 99%

Acute Stroke Biomarkers: Are We There Yet?

et al. 2021

View full text Add to dashboard Cite

Background: Distinguishing between stroke subtypes and knowing the time of stroke onset are critical in clinical practice. Thrombolysis and thrombectomy are very effective treatments in selected patients with acute ischemic stroke. Neuroimaging helps decide who should be treated and how they should be treated but is expensive, not always available and can have contraindications. These limitations contribute to the under use of these reperfusion therapies.Aim: An alternative approach in acute stroke diagnosis is to identify blood biomarkers which reflect the body's response to the damage caused by the different types of stroke. Specific blood biomarkers capable of differentiating ischemic from hemorrhagic stroke and mimics, identifying large vessel occlusion and capable of predicting stroke onset time would expedite diagnosis and increase eligibility for reperfusion therapies.Summary of Review: To date, measurements of candidate biomarkers have usually occurred beyond the time window for thrombolysis. Nevertheless, some candidate markers of brain tissue damage, particularly the highly abundant glial structural proteins like GFAP and S100β and the matrix protein MMP-9 offer promising results. Grouping of biomarkers in panels can offer additional specificity and sensitivity for ischemic stroke diagnosis. Unbiased “omics” approaches have great potential for biomarker identification because of greater gene, protein, and metabolite coverage but seem unlikely to be the detection methodology of choice because of their inherent cost.Conclusion: To date, despite the evolution of the techniques used in their evaluation, no individual candidate or multimarker panel has proven to have adequate performance for use in an acute clinical setting where decisions about an individual patient are being made. Timing of biomarker measurement, particularly early when decision making is most important, requires urgent and systematic study.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Stroke Biomarkers: Are We There Yet?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pathogens can also be detected with highly specific biosensors [ 60 , 61 ]. Most biosensors are comprised of a recognition element, a transduction element, and a system for detection, amplification and quantification of output signals.…”

Section: Methods For Identifying Infectious Agentsmentioning

confidence: 99%

Emerging Options for the Diagnosis of Bacterial Infections and the Characterization of Antimicrobial Resistance

Rentschler

Kaiser

Deigner

2021

IJMS

View full text Add to dashboard Cite

Precise and rapid identification and characterization of pathogens and antimicrobial resistance patterns are critical for the adequate treatment of infections, which represent an increasing problem in intensive care medicine. The current situation remains far from satisfactory in terms of turnaround times and overall efficacy. Application of an ineffective antimicrobial agent or the unnecessary use of broad-spectrum antibiotics worsens the patient prognosis and further accelerates the generation of resistant mutants. Here, we provide an overview that includes an evaluation and comparison of existing tools used to diagnose bacterial infections, together with a consideration of the underlying molecular principles and technologies. Special emphasis is placed on emerging developments that may lead to significant improvements in point of care detection and diagnosis of multi-resistant pathogens, and new directions that may be used to guide antibiotic therapy.

show abstract

“…The successful management of stroke is improved with its timely recognition even in pre-hospital settings (e.g., ambulance) [ 70 ]. Yet, currently used clinical methodologies, such as enzyme-linked immunosorbent assay (ELISA), mass spectrometry, electrochemiluminescence, immunoturbidimetry, and nephelometry, require sample pre-processing, complex laboratory instrumentation, and long testing procedures that overall limit the possibility to provide fast molecular profiles and disease management in decentralized settings [ 71 , 72 ]. Therefore, the need for novel technologies to deliver personalized information on-site for integration into a time-sensitive workflow has become critical.…”

Section: Conventional and Point-of-care Technologiesmentioning

confidence: 99%

Timely and Blood-Based Multiplex Molecular Profiling of Acute Stroke

Dias

Silva

Pinto

et al. 2021

Life

View full text Add to dashboard Cite

Stroke is a leading cause of death and disability in the world. To address such a problem, early diagnosis and tailored acute treatment represent one of the major priorities in acute stroke care. Since the efficacy of reperfusion treatments is highly time-dependent, there is a critical need to optimize procedures for faster and more precise diagnosis. We provide a concise review of the most relevant and well-documented blood–protein biomarkers that exhibit greater potential for translational to clinical practice in stroke differential diagnosis and to differentiate ischemic stroke from hemorrhagic stroke, followed by an overview of the most recent point-of-care technological approaches to address this problem. The integration of fluid-based biomarker profiling, using point-of-care biosensors with demographic, clinical, and neuroimaging parameters in multi-dimensional clinical decision-making algorithms, will be the next step in personalized stroke care.

show abstract

Recent Progress of Biomarker Detection Sensors

Cited by 49 publications

References 191 publications

Acute Stroke Biomarkers: Are We There Yet?

Acute Stroke Biomarkers: Are We There Yet?

Emerging Options for the Diagnosis of Bacterial Infections and the Characterization of Antimicrobial Resistance

Timely and Blood-Based Multiplex Molecular Profiling of Acute Stroke

Contact Info

Product

Resources

About